A New Perspective.
A Greater Connection.
Breaking Boundaries.
OPRIMED.
$185M.
100K+ components.
Endless variables.
In July 1969, Apollo 11 achieved the first successful
lunar landing in human history.
How did this bold leap succeed?
The secret to success
was 'digital simulation'
that reflected a variety
of conditions.
The secret to success
was 'digital simulation'
that reflected a variety
of conditions.
Big data? Cutting-edge AI? Specialized data?No. The secret was simply 'simulation'.
From rocket design to calculating precise fuel requirements and weight, determining launch positions and angles, and factoring in wind direction, weather,
and even environmental conditions, simulation technology
provided solutions for specific scenarios and was the
driving force behind the development of South Korea's
first spacecraft.
Big data? Cutting-edge AI? Specialized data?No. The secret was simply 'simulation'.
From rocket design to calculating precise fuel requirements and weight, determining launch
positions and angles, and factoring in wind direction,
weather, and even environmental conditions, simulation technology provided solutions for specific
scenarios and was the driving force behind the
development of South Korea's first spacecraft.
Big data? Cutting-edge AI? Specialized data?No. The secret was simply 'simulation'.
From rocket design to calculating precise fuel
requirements and weight, determining launch positions and angles, and factoring in wind direction, weather,
and even environmental conditions, simulation
technology provided solutions for specific scenarios
and was the driving force behind the development of
South Korea's first spacecraft.
Transforming the
Pharmaceutical IndustryThrough Infinite Digital Simulations
Transforming the
Pharmaceutical Industry
Through Infinite Digital Simulations
Simulation technology is revolutionizing
the pharmaceutical industry.
By recreating the real world into mathematical models
to build digital replicas and connecting them back to reality, the 'digital twin' enables real-time analysis and simulation. Through near-infinite iterative calculations and statistical
analysis, it finds optimal solutions, enhancing convenience,
productivity, and decision-making in our daily lives.
This remarkable digital twin technology is driving innovation across various industries.
Simulation technology is revolutionizing
the pharmaceutical industry.
By recreating the real world into mathematical models
to build digital replicas and connecting them back to reality, the 'digital twin' enables real-time analysis and simulation. Through near-infinite iterative calculations and statistical
analysis, it finds optimal solutions, enhancing convenience,
productivity, and decision-making in our daily lives.
This remarkable digital twin technology is driving innovation across various industries.
OPRIMED Inc., Revolutionizing
Drug Development with Human Digital Twin Technology
OPRIMED Inc., Revolutionizing
Drug Development with Human Digital Twin Technology
OPRIMED Inc. is taking on the challenge of transforming the pharmaceutical industry with its groundbreaking human digital twin technology.
Developed using OPRIMED Inc.’s advanced AI technology that integrates diverse datasets, the Human Digital Twin facilitates digital-based research to uncover new evidence, generate insights into disease treatment, and drive innovation throughout the entire drug development
and disease management process.
OPRIMED Inc. is taking on the challenge of transforming the pharmaceutical industry with its groundbreaking human digital twin technology.
Developed using OPRIMED Inc.’s advanced AI technology that integrates diverse datasets, the Human Digital Twin facilitates digital-based research to uncover new evidence, generate insights into disease treatment, and drive innovation throughout the entire drug development
and disease management process.
About
Why OPRIMED?
OPRIMED fuses deep pharmaceutical expertise with
cutting-edge AI, delivering innovative solutions that address
everything from patient variability to complex regulatory
guidelines. We lead the way in meeting the advanced demands
of the pharmaceutical industry with a holistic perspective,
setting a new standard for the future of healthcare.
OPTIVIS:
A Digital Twin
Technology
by OPRIMED
OPRIMED OPTIVIS precisely replicates individual characteristicsto revolutionize personalized drug development through next-generation digital twins.
OPTIVIS, a technology by OPRIMED that applies a methodology recognized by regulatory
authorities and delivers world-leading results, creates virtual patients that cannot be
distinguished statistically from real patients.
Digital Twin: A virtual digital model (virtual patient) identical to the physical model (real patient).
Benefits of Using OPTIVIS
Considering the significant costs and timelines associated with pharmaceutical R&D, especially the 91% spent on candidate discovery and clinical stages, OPTIVIS’ virtual patient simulation services deliver remarkable benefits:
Up to
%
fewer patients
Up to
%
shorter trials
*Database : ClinicalTrials.gov
At least
X
higher success rate
Approx.
.
billion USD
saved
*HealthDatabase : IMS
Technology
OPRIMED
Unparalleled
Technological Expertise
1
Digital Twin
Clinical Trial Technology
Digital Twin
Clinical Trial
Technology
Uses real patient data to create statistically matchedvirtual subjects, achieving high reliability with fewer
participants and significantly reducing trial time
and cost.
Uses real patient data to create statistically matched virtual
subjects, achieving high reliability with fewer participants and
significantly reducing trial time and cost.
2
Hybrid Trial Design
Hybrid Trial Design
Integrates real and virtual patient groups to form a control group, enabling precise treatment analysis
while minimizing ethical and practical burdens.
Integrates real and virtual patient groups to form a control
group, enabling precise treatment analysis while minimizing
ethical and practical burdens.
3
Advanced
Machine Learning
Prediction
Processes large-scale medical data to forecast
trial outcomes and automates decision-making,
boosting overall research efficiency and success
rates.
Services
OPRIMED Offers Clinical and Pharmaceutical Simulation Services
A
Virtual Patient Generation and Management Platform,
OPTIVIS NEXUS
01/
Virtual patient-based clinical trial design
Generation of virtual clinical patients
(external control groups)
02/
Hybrid clinical trial design
03/
External control arm design
04/
Real-time clinical trial analysis
05/
Patient count and optimal patient prediction
06/
Clinical trial success rate analysis
B
Clinical Trial Design Platform,OPTIVIS Trials
01/
Clinical trial duration prediction
02/
Patient dropout rate prediction
03/
Serious adverse event prediction
04/
Mortality prediction
05/
Clinical trial approval outcome prediction
06/
Root cause analysis of trial failures
07/
Drug dosage optimization
08/
Patient eligibility criteria design
Pipeline
1st Phase
Securing a Competitive Edge
Through Data Driven
Technology
2nd Phase
Building Trust
Through Clinical Validation
and Regulatory Certifications
Final Phase
Expanding Globally
With Operations Based in
the UK and the US
2023
2025
2027
OPRIMED is set to leap into
the global market, serving 7 million customers and targeting a market worth 406 trillion KRW.
577,099
Total Domestic Customers
7,615,569
Total Customers Across 16 Countries
Source: Korea Institute of Science and Technology Evaluation
Partners
OPRIMED is dedicated to becoming a trusted partner
for all stakeholders involved in drug development research.
OPRIMED is dedicated to
becoming a trusted partner
for all stakeholders involved
in drug development research.
Universities
Pharmaceutical
Companies
Government
Agencies
Research
Institutions
Hospitals
Universities
Pharmaceutical
Companies
Government
Agencies
Research
Institutions
Hospitals
Teams
Experts excelling in problem-solving across various fields have come together.
OPRIMED, a group of specialists deeply knowledgeable in both AI and the pharmaceutical industry.
Our mission and technology have the potential to change the world.
We do not hesitate to embrace new discoveries and challenges. With professionalism and expertise, we drive innovation in the pharmaceutical industry. We communicate actively and prove our value through results.
Research Team
Biology
Specialist
Medical
Specialist
Clinical Trial Specialist
AI
Specialist
Network
Text
Image
Sequence Data
User Experience
Specialist
BusinessTeam
Finance
Business Strategy
A New Perspective.
A Greater Connection.
Breaking Boundaries.
OPRIMED.
A New Perspective.
A Greater Connection.
Breaking Boundaries.
OPRIMED.
$185M.
100K+ components. Endless variables.
In July 1969, Apollo 11
achieved the first successful
lunar landing in human history.
How did this
bold leap succeed?
The secret to success was 'digital simulation' that reflected a variety of conditions.
Big data? Cutting-edge AI? Specialized data? No. The secret was simply 'simulation'.
From rocket design to calculating precise fuel requirements and weight, determining launch positions and angles, and factoring in wind direction, weather, and even environmental conditions, simulation technology provided solutions for specific scenarios and was the driving force behind the development of South Korea's first spacecraft.
About
Why
OPRIMED?
OPRIMED fuses deep
pharmaceutical expertise
with cutting-edge AI,
delivering innovative
solutions that address
everything from patient
variability to complex
regulatory guidelines.
We lead the way in meeting
the advanced demands of
the pharmaceutical industry
with a holistic perspective, setting a new standard for
the future of healthcare.
OPTIVIS:
A Digital Twin Technology by OPRIMED
OPRIMED OPTIVIS precisely
replicates individual
characteristics to revolutionize personalized drug
development through
next-generation digital twins.
OPTIVIS, a technology by OPRIMED that applies a methodology recognized by regulatory authorities and delivers world-leading results,
creates virtual patients that cannot be
distinguished statistically from real patients.
Digital Twin: A virtual digital model (virtual patient) identical to
the physical model (real patient).
Benefits of
Using OPTIVIS
Considering the significant costs and timelines associated with pharmaceutical R&D, especially the 91% spent on candidate discovery and clinical stages, OPTIVIS’ virtual patient simulation services deliver remarkable benefits:
Up to
%
fewer patients
Up to
%
shorter trials
*Database : ClinicalTrials.gov
At least
X
higher success rate
Approx.
.
billion USD
saved
*HealthDatabase : IMS
Technology
OPRIMED
Unparalleled
Technological
Expertise
1
Digital Twin
Clinical Trial Technology
Uses real patient data to create statistically matched virtual subjects, achieving high reliability with fewer participants and significantly reducing trial time and cost.
2
Hybrid Trial Design
Integrates real and virtual patient groups to form a control
group, enabling precise treatment analysis while minimizing
ethical and practical burdens.
3
Advanced
Machine Learning Prediction
Processes large-scale medical data to forecast trial
outcomes andautomates decision-making, boosting
overall research efficiency and success rates.
Services
OPRIMED Offers Clinical and Pharmaceutical Simulation Services
A
Virtual Patient Generation
and Management Platform,
OPTIVIS NEXUS
01/
Virtual patient-based clinical trial design
02/
Hybrid clinical trial design
03/
External control arm design
04/
Real-time clinical trial analysis
05/
Patient count and
optimal patient prediction
06/
Clinical trial success rate analysis
B
Clinical Trial Design Platform, OPTIVIS Trials
01/
Clinical trial duration prediction
02/
Patient dropout rate prediction
03/
Serious adverse event prediction
04/
Mortality prediction
05/
Clinical trial approval
outcome prediction
06/
Root cause analysis
of trial failures
07/
Drug dosage optimization
08/
Patient eligibility criteria design
OPRIMED is
set to leap into the global market, serving 7 million customers and targeting a market worth 406 trillion KRW.
Total Domestic Customers
Total Customers Across 16 Countries
Source: Korea Institute of Science
and Technology Evaluation
Pipeline
1st Phase ( '23 )
Securing a Competitive Edge
Through Data-Driven
Technology
2nd Phase ( '25 )
Building Trust
Through Clinical Validation
and Regulatory Certifications
Final Phase ( '27 )
Expanding Globally
With Operations Based in
the UK and the US
Partners
OPRIMED is dedicated to becoming a trusted partner for all stakeholders involved in drug development research.
Universities
Pharmaceutical
Companies
Government
Agencies
Research
institutions
Hospitals
Teams
Experts excelling in problem-solving across various fields have come together.
OPRIMED, a group of specialists
deeply knowledgeable in both AI and the pharmaceutical industry.
Our mission and technology have the potential to change the world. We do not hesitate to embrace new discoveries and challenges. With professionalism and expertise, we drive innovation in the pharmaceutical industry. We communicate actively and prove our value through results.
Data
Science
Team
Medical
Specialist
Biology
Specialist
Clinical Trial Specialist
AI
Specialist
Network
Text
Image
Sequence Data
User Experience
Specialist
Business
Team
Finance
Business
Strategy
Transforming the Pharmaceutical Industry Through Infinite Digital Simulations
Simulation technology is revolutionizing the pharmaceutical industry.
By recreating the real world into mathematical models to build digital replicas and connecting them back to reality, the 'digital twin' enables real-time analysis and simulation. Through near-infinite iterative calculations and statistical analysis, it finds
optimal solutions, enhancing convenience, productivity, and decision-making in our daily lives. This remarkable digital twin technology is driving innovation across various industries.
OPRIMED Inc., Revolutionizing Drug Development with Human Digital Twin Technology
OPRIMED Inc. is taking on the challenge of transforming the pharmaceutical industry with its groundbreaking human digital twin technology.
Developed using OPRIMED Inc.’s advanced AI technology that integrates diverse datasets, the Human Digital Twin facilitates digital-based research to uncover new evidence, generate insights into disease treatment, and drive innovation throughout the entire drug development and disease management process.
© 2025 OPRIMED Inc. (All Rights Reserved)
Connecting to
a Better Future
Meet OPRIMED today.
Recruiting
|
Notices
|
Contact
OPRIMED Inc.
CEO Suji Hong
Business Registration Number
277-87-02894
Headquarters (Ulsan)
Room 601, Ulsan Startup Hub,
Jongha Innovation Center,
32, Bongwol-ro 38beon-gil,
Nam-gu, Ulsan, South Korea
Big Data Lab (Suwon)
10th Floor, Room 1001, Gwanggyo Central Business Tower,
260 Changnyong-daero, Yeongtong-gu, Suwon,
Gyeonggi Province
info@oprimed.com
OPRIMED Inc.
CEO Suji Hong
Business Registration Number
277-87-02894
Headquarters (Ulsan)
Room 601, Ulsan Startup Hub,Jongha Innovation Center,
32, Bongwol-ro 38beon-gil,
Nam-gu, Ulsan, South Korea
info@oprimed.com
Big Data Lab (Suwon)
10th Floor, Room 1001,
Gwanggyo Central Business
Tower, 260 Changnyong-daero, Yeongtong-gu, Suwon,
Gyeonggi Province
© 2025 OPRIMED INC. (All Rights Reserved)